ONOCOR

Executive Summary

ONOCOR Vascular is a privately held medical device company headquartered in San Diego, California, founded in 2018. The company is pioneering a novel catheter-based retrieval system designed to percutaneously remove misplaced, embolized, or malfunctioning cardiovascular implants. This technology addresses a critical unmet need in interventional cardiology and structural heart procedures, where implant malposition or device failure can lead to life-threatening complications. By providing a minimally invasive 'safety net,' ONOCOR's system has the potential to avoid high-risk remedial open-heart surgery, thereby reducing patient morbidity, hospital stays, and healthcare costs. The platform targets a growing market driven by the increasing adoption of transcatheter heart valves, left atrial appendage occluders, and other percutaneous implants, which inherently carry risks of embolization or misplacement. ONOCOR's solution could become an essential tool in the catheterization lab, analogous to how snares and retrieval baskets are used in other endovascular procedures. As a pre-commercial entity, ONOCOR is likely focused on advancing its technology through preclinical testing and early-stage clinical validation. The company's success hinges on demonstrating safety and efficacy in human trials, securing regulatory clearance (likely FDA 510(k) or De Novo pathway), and establishing reimbursement codes. With no disclosed funding rounds or partnerships, ONOCOR may be operating in stealth mode or relying on angel/seed investment. Given the significant market opportunity (the global transcatheter heart valve market alone is expected to exceed $10 billion by 2030), a successful entry could position ONOCOR for acquisition by larger cardiovascular device firms such as Edwards Lifesciences, Medtronic, or Abbott. However, execution risks include technical challenges in device design (e.g., grasping various implant geometries without causing damage), competition from existing retrieval tools, and the need for specialized physician training.

Upcoming Catalysts (preview)

• Q2 2027Completion of first-in-human clinical study40% success
• Q1 2027Series A financing round60% success
• Q4 2027Strategic partnership with a major cardiovascular device company30% success